IVI Watch [to 3 January 2014]
http://www.ivi.org/web/www/home

IVI and SK Chemicals Receive Funding to Advance Development of a New Typhoid Vaccine
IVI partnering with SK Chemicals on vaccine research and development
4.9 million USD grant from Gates Foundation to support typhoid vaccine early clinical trials

SEOUL, SOUTH KOREA – The International Vaccine Institute (IVI) announced today that grant funding of 4.9 million USD was received from the Bill & Melinda Gates Foundation to support clinical research and development of a new typhoid fever vaccine in collaboration with SK Chemicals. The grant is effective from December 2014 to September 2017…
…IVI developed a new typhoid vaccine based on conjugation of the bacterial Vi polysaccharide antigen, conjugated to diphtheria toxoid (DT). Compared with current typhoid vaccines, it has the potential to protect children below two years old and to provide protection against typhoid for a longer duration of time. SK Chemicals has gained extensive technology and expertise on conjugate vaccines from its experience with the pneumococcal conjugate vaccine. By combining this with the technology transferred from IVI, SK Chemicals has successfully established the manufacturing process for the typhoid vaccine at a commercial scale…
…The new grant will support early clinical trials for the typhoid conjugate vaccine. IVI will work with SK Chemicals in the development and conduct of clinical trials for vaccine licensure and eventually WHO prequalification…